2024
Novel and emerging tests for food allergy
Liu E, Eisenbarth S. Novel and emerging tests for food allergy. 2024, 698-709. DOI: 10.1016/b978-0-323-96018-2.00081-x.Peer-Reviewed Original ResearchFood allergyActivation testingSkin prick testingRisk of developmentAvailable clinical testsSkin barrier permeabilityLow predictive valueInflammatory markersPrick testingIgE testingImmunoglobulin EBarrier permeabilityAllergyPromising biomarkerPredictive valueClinical testsGenetic testingLack of testingCellular profilingMarkersWidespread useTestingImmunoglobulinBiomarkersSeverity
2022
Inclusion of social determinants of health improves sepsis readmission prediction models
Amrollahi F, Shashikumar S, Meier A, Ohno-Machado L, Nemati S, Wardi G. Inclusion of social determinants of health improves sepsis readmission prediction models. Journal Of The American Medical Informatics Association 2022, 29: 1263-1270. PMID: 35511233, PMCID: PMC9196687, DOI: 10.1093/jamia/ocac060.Peer-Reviewed Original ResearchConceptsUnplanned readmissionSepsis patientsReadmission modelsClinical/laboratory featuresSocial determinantsUnplanned hospital readmissionHigh-risk patientsObjective clinical dataLow predictive valueReadmission prediction modelsSepsis readmissionsLaboratory featuresSepsis casesHospital readmissionPredictive factorsClinical dataReadmissionHigh riskPredictive valueSDH factorsMedical carePatientsDemographic featuresLarger studyProgram cohort
2013
Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study. Clinical Breast Cancer 2013, 13: 254-263. PMID: 23829891, PMCID: PMC4084778, DOI: 10.1016/j.clbc.2013.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'PrognosisReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival RateTamoxifenYoung AdultConceptsTrastuzumab-based therapyFirst-line trastuzumab-based therapyAdvanced HER2-positive breast cancerHER2-positive breast cancerAdjuvant trastuzumabBreast cancerClinicopathological featuresClinical benefitC-statisticHuman epidermal growth factor-2-positive breast cancerTreatment durationPredictive valueHormone receptor-positive tumorsLong-term clinical benefitPrevious adjuvant trastuzumabTreatment duration groupsRetrospective cohort studyDisease-free intervalHormone receptor positivityReceptor-positive tumorsDuration of treatmentMagnitude of benefitLow predictive valueLogistic regression modelsDifferent logistic regression models
1997
Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.
Salloum E, Brandt D, Caride V, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper D. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Journal Of Clinical Oncology 1997, 15: 518-27. PMID: 9053473, DOI: 10.1200/jco.1997.15.2.518.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantChildFemaleGallium RadioisotopesHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRadiotherapy, AdjuvantTomography, Emission-Computed, Single-PhotonTreatment OutcomeConceptsNegative 67Ga scanPositive 67Ga scanTime of diagnosisManagement of patientsHodgkin's diseaseStage IIIStage IPredictive valueGallium scanGross residual diseaseEnd of therapyNegative predictive valueLow predictive valueModality therapyProgressive diseaseResidual diseasePositive scansRadiation therapyPatientsTherapyDiseaseScansTreatmentDiagnosisChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply